MedPath

Clinical study on the treatment of uric acid nephropathy by high colon route of Yiqing Recipe

Not Applicable
Conditions
ric acid nephropathy
Registration Number
ITMCTR2100005124
Lead Sponsor
Shenzhen Second People's Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Diagnostic criteria: meet the diagnostic criteria for uric acid nephropathy;
2. Patients with chronic kidney disease (CKD) stage 1-4;
3. Aged 16 to 78 years;
4. Patients who accept this study and agree to sign the informed consent form, who can cooperate on time;
5. TCM syndrome classification and quantification basis: refer to the Guidelines for Clinical Research on New Chinese Medicines and Uric Acid Nephropathy Diagnosis, Syndrome Differentiation and Efficacy Judgment designated by the Nephrology Branch of the Chinese Traditional Chinese Medicine Association in 2008, which belong to the spleen and kidney. Patients with qi deficiency, liver and kidney yin deficiency, qi and yin deficiency, concurrent wet turbidity, and blood stasis syndrom;
6. Those who did not use traditional Chinese medicine or western medicine to lower uric acid in the 2 weeks before the test, or those who used related drugs but stopped for more than 2 weeks to wash out;
7. For long-term use of hydrochlorothiazide and other drugs that affect blood uric acid, and can replace other drugs, a 2-week washout period after stopping and changing the drug.

Exclusion Criteria

1. Renal damage or secondary hyperuricemia caused by other reasons;
2. Taking other drugs that affect renal function;
3. Patients with acute severe infection lesions;
4. Patients with severe colorectal diseases such as hemorrhoids and anal fistula;
5. Patients with serious primary diseases such as heart, kidney, liver, brain, and hematopoietic system, and are in the acute exacerbation stage;
6. Pregnant or lactating women;
7. Those who are allergic to allopurinol or have a positive HLA-B 5801 gene test.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eutrophil ratio;Prothrombin time;Right kidney glomerular filtration rate;Total glomerular filtration rate;24h urine protein quantification;Cystatin C;interleukin-4;C reactive protein;interleukin-2;platelet count;Serum creatinine;Urine protein;Urine NAG enzyme;alanine aminotransferase;urea nitrogen;Homocysteine;Urine red blood cells;albumin;Red blood cell count;Interferon-?;Urine osmotic pressure;Lymphocyte ratio;blood uric acid;Tumor necrosis factor-a;Left kidney glomerular filtration rate;interleukin-6;interleukin-10;
Secondary Outcome Measures
NameTimeMethod
hemoglobin;Urine PH;Direct bilirubin;White blood cell count;Indirect bilirubin;Urine Leukocytes;Urine Specific Gravity;Total bilirubin;
© Copyright 2025. All Rights Reserved by MedPath